BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24441285)

  • 1. Radiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy.
    Kerns SL; Ostrer H; Rosenstein BS
    Cancer Discov; 2014 Feb; 4(2):155-65. PubMed ID: 24441285
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.
    Rosenstein BS
    Pharmacogenomics; 2011 Feb; 12(2):267-75. PubMed ID: 21332318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiogenomics: towards a personalized radiation oncology.
    Roberson JD; Burnett OL; Robin N
    Curr Opin Pediatr; 2016 Dec; 28(6):713-717. PubMed ID: 27552070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiogenomics: the search for genetic predictors of radiotherapy response.
    Kerns SL; West CM; Andreassen CN; Barnett GC; Bentzen SM; Burnet NG; Dekker A; De Ruysscher D; Dunning A; Parliament M; Talbot C; Vega A; Rosenstein BS
    Future Oncol; 2014 Dec; 10(15):2391-406. PubMed ID: 25525847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiogenomics - current status, challenges and future directions.
    Andreassen CN; Schack LM; Laursen LV; Alsner J
    Cancer Lett; 2016 Nov; 382(1):127-136. PubMed ID: 26828014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Finding the genetic determinants of adverse reactions to radiotherapy.
    Rattay T; Talbot CJ
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):301-8. PubMed ID: 24702740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiogenomics: radiobiology enters the era of big data and team science.
    Rosenstein BS; West CM; Bentzen SM; Alsner J; Andreassen CN; Azria D; Barnett GC; Baumann M; Burnet N; Chang-Claude J; Chuang EY; Coles CE; Dekker A; De Ruyck K; De Ruysscher D; Drumea K; Dunning AM; Easton D; Eeles R; Fachal L; Gutiérrez-Enríquez S; Haustermans K; Henríquez-Hernández LA; Imai T; Jones GD; Kerns SL; Liao Z; Onel K; Ostrer H; Parliament M; Pharoah PD; Rebbeck TR; Talbot CJ; Thierens H; Vega A; Witte JS; Wong P; Zenhausern F;
    Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):709-13. PubMed ID: 24969789
    [No Abstract]   [Full Text] [Related]  

  • 8. Genome-wide association studies and prediction of normal tissue toxicity.
    West CM; Dunning AM; Rosenstein BS
    Semin Radiat Oncol; 2012 Apr; 22(2):91-9. PubMed ID: 22385916
    [No Abstract]   [Full Text] [Related]  

  • 9. Radiogenomics in lung cancer: Where are we?
    Aguado-Barrera ME; Sosa-Fajardo P; Gómez-Caamaño A; Taboada-Valladares B; Couñago F; López-Guerra JL; Vega A
    Lung Cancer; 2023 Feb; 176():56-74. PubMed ID: 36621035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular determinants of radiosensitivity in normal and tumor tissue: A bioinformatic approach.
    Pavlopoulou A; Bagos PG; Koutsandrea V; Georgakilas AG
    Cancer Lett; 2017 Sep; 403():37-47. PubMed ID: 28619524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiogenomics: Identification of Genomic Predictors for Radiation Toxicity.
    Rosenstein BS
    Semin Radiat Oncol; 2017 Oct; 27(4):300-309. PubMed ID: 28865512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy.
    Azria D; Ozsahin M; Kramar A; Peters S; Atencio DP; Crompton NE; Mornex F; Pèlegrin A; Dubois JB; Mirimanoff RO; Rosenstein BS
    Clin Cancer Res; 2008 Oct; 14(19):6284-8. PubMed ID: 18829510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project.
    Ho AY; Atencio DP; Peters S; Stock RG; Formenti SC; Cesaretti JA; Green S; Haffty B; Drumea K; Leitzin L; Kuten A; Azria D; Ozsahin M; Overgaard J; Andreassen CN; Trop CS; Park J; Rosenstein BS
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):646-55. PubMed ID: 16751059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiogenomics: A systems biology approach to understanding genetic risk factors for radiotherapy toxicity?
    Herskind C; Talbot CJ; Kerns SL; Veldwijk MR; Rosenstein BS; West CM
    Cancer Lett; 2016 Nov; 382(1):95-109. PubMed ID: 26944314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic markers for prediction of normal tissue toxicity after radiotherapy.
    Alsner J; Andreassen CN; Overgaard J
    Semin Radiat Oncol; 2008 Apr; 18(2):126-35. PubMed ID: 18314067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects.
    Bentzen SM; Parliament M; Deasy JO; Dicker A; Curran WJ; Williams JP; Rosenstein BS
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3 Suppl):S145-50. PubMed ID: 20171510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAPPER: the radiogenomics of radiation toxicity.
    Burnet NG; Barnett GC; Elliott RM; Dearnaley DP; Pharoah PD; Dunning AM; West CM;
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):431-4. PubMed ID: 23642504
    [No Abstract]   [Full Text] [Related]  

  • 18. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.
    Kerns SL; Dorling L; Fachal L; Bentzen S; Pharoah PD; Barnes DR; Gómez-Caamaño A; Carballo AM; Dearnaley DP; Peleteiro P; Gulliford SL; Hall E; Michailidou K; Carracedo Á; Sia M; Stock R; Stone NN; Sydes MR; Tyrer JP; Ahmed S; Parliament M; Ostrer H; Rosenstein BS; Vega A; Burnet NG; Dunning AM; Barnett GC; West CM;
    EBioMedicine; 2016 Aug; 10():150-63. PubMed ID: 27515689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a Radiogenomics Consortium.
    West C; Rosenstein BS; Alsner J; Azria D; Barnett G; Begg A; Bentzen S; Burnet N; Chang-Claude J; Chuang E; Coles C; De Ruyck K; De Ruysscher D; Dunning A; Elliott R; Fachal L; Hall J; Haustermans K; Herskind C; Hoelscher T; Imai T; Iwakawa M; Jones D; Kulich C; ; Langendijk JH; O'Neils P; Ozsahin M; Parliament M; Polanski A; Rosenstein B; Seminara D; Symonds P; Talbot C; Thierens H; Vega A; West C; Yarnold J
    Int J Radiat Oncol Biol Phys; 2010 Apr; 76(5):1295-6. PubMed ID: 20338472
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement.
    De Ruysscher D; Defraene G; Ramaekers BLT; Lambin P; Briers E; Stobart H; Ward T; Bentzen SM; Van Staa T; Azria D; Rosenstein B; Kerns S; West C
    Radiother Oncol; 2016 Dec; 121(3):440-446. PubMed ID: 27979370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.